Zhaojin Yu, M.M.

626-218-5628
Zhaojin Yu, M.M.
Visiting Scholar, Department of Systems Biology
Research Area
  • Epigenetic Modification of RNA in Cancer
  • Translational Research
Research Teams
Systems Biology
Zhaojin Yu came from China and acquired his master degree in pharmacology from China Medical University in 2010. Before coming to City of Hope, he worked as an assistant professor and researcher at China Medical University’s School of Pharmacy; his work primarily focused on cancer immunology therapy. Zhaojin Yu joined the Department of Systems Biology of the Beckman Research Institute in February 2019 as a visiting scholar.  He is currently conducting research in the area of biological and biomedical sciences with a focus on RNA epigenetics and translational research.
 

Location

Education & Experience

Degrees

  • 2015 – present, Ph.D., Pharmacology, China Medical University, China

  • 2010, M.M., Pharmacology, China Medical University, China

  • 2006, B.M., Forensic Medicine, China Medical University, China

Professional Experience

  • 2019 – present, Visiting Scholar, Department of Systems Biology, City of Hope Beckman Research Institute, Monrovia, CA

  • 2016 – 2012, Assistant Professor and Researcher, Department of Pharmacology, School of Pharmacy, China Medical University

  • 2011-2016, Lecturer, Department of Pharmacology, School of Pharmacy, China Medical University

  • 2010-2011, Teaching Assistant, Department of Pharmacology, School of Pharmacy, China Medical University

Awards & Memberships

Awards

  • 2017, First Prize in Shenyang Science and Technology Progress Award - "Basic and Clinical Research on Specific Markers and Regulatory Networks Mediating Breast Cancer Drug Sensitivity"

  • 2016, First Prize in Liaoning Province Medical Science and Technology Award

Publications

  • Yu Z, Xiao Q, Zhao L, Ren J, Bai X, Sun M, Wu H, Liu X, Song Z, Yan Y, Mi X, Wang E, Jin F, Wei M*. DNA methyltransferase 1/3a overexpression in sporadic breast cancer is associated with reduced expression of estrogen receptor-alpha/breast cancer susceptibility gene 1 and poor prognosis. Mol Carcinog, 54(9):707-19, 2015. IF:4.722
  • Yu Z, Sun M, Jin F, Xiao Q, He M, Wu H, Ren J, Zhao L, Zhao H, Yao W, Shan F, Cao Y, Wei M*. Combined expression of ezrin and E-cadherin is associated with lymph node metastasis and poor prognosis in breast cancer. Oncol Rep, 4(1):165-74, 2015. IF:2.486.
  • Zhao H, Yu Z, Zhao L, He M, Ren J, Wu H, Chen Q, Yao W, Wei M*. HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy. Jpn J Clin Oncol, 46(10):893-902, 2016. IF:1.889.
  • Zhang Y, Yu Z, Xiao Q, Sun X, Zhu Z, Zhang J, Xu H, Wei M*, Sun M. Expression of BAMBI and its combination with Smad7 correlates with tumor invasion and poor prognosis in gastric cancer. Tumour Biol, 35(7):7047-56, 2014. IF:3.611.
  • Zhao L, Yu Z, Li Y, Wen X, Ma W, Wang L, Ren J, Liu C, He M, Bai X, Sun M, Zheng Z, Mi X, Wang E, Olopade OI, Jin F, Wei M*. Clinical implications of ERβ methylation on sporadic breast cancers in Chinese women. Med Oncol, 29(3):1569-75, 2012. IF:2.147.